Kaunas-based medtech startup BrachyDOSE, which develops a medical device that measures radiation doses during cancer treatment, has secured €554,000 in funding to test its technology in a clinical environment, as Vestbee was informed.
- BrachyDOSE was founded in January 2024 by Neringa Šeperienė and Rimas Šeperys. The company develops a radiation dose measurement device used during cancer radiotherapy.
- The system includes a disposable sensor shaped like a flexible tube, which is placed near the tumor before treatment. During the procedure, the sensor measures the actual radiation dose in real time. After treatment, the sensor is removed, scanned, and the collected data is transferred to a computer.
- The software analyzes this data using a machine learning–based algorithm. It identifies mismatches between the prescribed and delivered doses and provides information on the likelihood and type of potential injuries.
Details of the deal
- The fresh capital was led by venture capital fund Coinvest Capital, which contributed €300,000 as the lead investor, with participation from BSV Ventures, a €15 million fund focusing on Deep Tech, Life Science, and Dual-Use technologies, and business angel networks LitBAN and EstBAN.
"BrachyDOSE stands out for its versatility and broad applicability; the technology can be used in any oncology hospital worldwide. This is encouraging news for investors, but more importantly, it may be good news for cancer patients and oncology professionals alike,” claims Viktorija Trimbel, Managing Director of Coinvest Capital.
- BrachyDOSE aims to finalize the CE and Medical Device Regulation (MDR) certification processes, enabling the company to launch its radiation measurement technology in both Lithuanian and international markets.
- Additionally, BrachyDOSE plans to expand its team, including hiring a medical device salesperson, and strengthen partnerships with oncology hospitals to accelerate adoption and improve the precision and safety of cancer radiotherapy treatments worldwide.
“We are grateful to the venture funds and angel investors who have supported us on our journey. Once we obtain CE/MDR certification, we will be able to offer our product to both Lithuanian and international markets," founder and CEO of BrachyDOSE, Neringa Šeperienė, commented in a press release.
